Results 31 to 40 of about 1,900 (132)

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials

open access: yesEuropean Journal of Heart Failure, Volume 27, Issue 6, Page 994-1002, June 2025.
Among high‐risk patients with type 2 diabetes, new oral loop diuretic intensification was frequent and portended adverse prognostic significance. Treatment with canagliflozin significantly reduced the need for loop diuretic intensification. CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; HF, heart failure; HR, hazard ratio ...
Safia Chatur   +11 more
wiley   +1 more source

Treatment and outcome of gall bladder leiomyoma in an asymptomatic dog

open access: yesVeterinary Record Case Reports, Volume 13, Issue 2, June 2025.
Abstract The purpose of this report was to describe the diagnostic protocol, treatment and outcome of an 11‐year‐old, entire male, mixed‐breed dog with a gall bladder neoplasia histologically consistent with a leiomyoma. On referral, the patient had no clinical signs related to the gall bladder mass.
Elisa Pizzi   +4 more
wiley   +1 more source

A publicidade de alimentos e o direito à saúde

open access: yesRevista de Direito Sanitário, 2007
Este trabalho analisa a monitoração e fiscalização da propaganda de produtos sujeitos à vigilância sanitária, um processo influenciado por mudanças sociais e econômicas, pela evolução da ciência e pelo ordenamento jurídico.
Maria José Delgado Fagundes   +1 more
doaj  

Expert opinion on gray areas in asthma management: A lesson from the innovative project “revolution in asthma” of the Italian thoracic society (AIPO‐ITS)

open access: yesClinical and Translational Allergy, Volume 15, Issue 2, February 2025.
Abstract Background Despite the availability of numerous guidelines for asthma management, their recommendations are not consistently implemented in clinical practice. This discrepancy between guidelines and real‐world practice among Italian healthcare professionals was explored during the “Revolution in Asthma” training program, which identified “gray
Adriano Vaghi   +17 more
wiley   +1 more source

Drug Discovery Approaches to Target E3 Ligases

open access: yesChemBioChem, Volume 26, Issue 1, January 2, 2025.
Comprehensive review presenting the different drug discovery approaches that until now have been employed in academic and pharmaceutical settings to identify new E3 ligase small molecules ligands and contributing to the expansion of the targeted protein degradation field. Abstract Targeting E3 ligases is a challenging area in drug discovery.
Alejandra Rodríguez‐Gimeno   +1 more
wiley   +1 more source

Endoaesthetic Management of Type II Dens Invaginatus Associated With Root Perforation and Apical Abscess: A Case Report

open access: yesCase Reports in Dentistry, Volume 2025, Issue 1, 2025.
Dens invaginatus (DI) is a developmental anomaly that affects teeth. This case report demonstrates the successful endoaesthetic management of a Type II DI in the maxillary right lateral incisor (Tooth 12). A 12‐year‐old female patient presented with pain and swelling in Tooth 12, which had previously been diagnosed with DI and accessed endodontically ...
Alessandro Moreira Freire   +9 more
wiley   +1 more source

Saúde, medicamentos, marketing e médicos

open access: yesRevista Portuguesa de Medicina Geral e Familiar, 2008
O presente artigo introduz uma visão muito sintética da situação da Saúde em Portugal e do seu posicionamento em relação a outros países com um grau de desenvolvimento semelhante.
Luís Dos Santos Ferreira
doaj   +1 more source

The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3‐ITD‐Mutant Acute Myeloid Leukaemia

open access: yesJournal of Cellular and Molecular Medicine, Volume 28, Issue 23, December 2024.
ABSTRACT MEN1703 is a first‐in‐class, oral, Type I dual PIM/FMS‐like tyrosine kinase 3 inhibitor (FLT3i) investigated in a Phase I/II DIAMOND‐01 trial in patients with acute myeloid leukaemia (AML). Gilteritinib is a highly potent and selective oral FLT3i approved for the treatment of relapsed/refractory AML with FLT3 mutations.
Sonia Zicari   +16 more
wiley   +1 more source

Fossil fuel industry influence in higher education: A review and a research agenda

open access: yesWIREs Climate Change, Volume 15, Issue 6, November/December 2024.
A growing research agenda: Timeline of the cumulative number of news articles (black, left axis), white paper reports (red, right axis), and peer‐reviewed and academic publications (green, right axis) concerning fossil fuel industry ties to higher education.
Sofia Hiltner   +5 more
wiley   +1 more source

INOVAÇÕES NA INDÚSTRIA FARMACÊUTICA - ESTUDO DE UMA INDÚSTRIA DE MEDICAMENTOS GENÉRICOS

open access: yesCaderno de Administração, 2017
Uma característica importante para definir a indústria farmacêutica são os altos investimentos em pesquisa, desenvolvimento e inovação (PD&I), em parceria com outras instituições, o que possibilitou um ritmo alto de inovações desenvolvidas nos últimos ...
Maira UEZ   +2 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy